The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
KEYNOTE-590: Phase III Study of First-Line Chemotherapy with or Without Pembrolizumab for Advanced Esophageal Cancer
Open accessAbstract
BACKGROUND: Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer. AIM: To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer. Clinical trial registry & ID: ClinicalTrials.gov : NCT03189719.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0013 · Cited by 1,784
Self-citation
Cited by
Zhang, W., Bhagwath, A. S., Ramzan, Z., Williams, T. A., Subramaniyan, I., Edpuganti, V., Kallem, R. R., Dunbar, K. B., Ding, P., Gong, K., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0638 · Cited by 33
Metadata
- Authors
- Kato, K., Shah, M. A., Enzinger, P., Bennouna, J., Shen, L., Adenis, A., Sun, J.-M., Cho, B. C., Özgüroğlu, M., Kojima, T., Kostorov, V., Hierro, C., Zhu, Y., McLean, L. A., Shah, S., & Doi, T.
- Venue
- Future Oncology
- Publisher
- Informa UK Limited
- Published
- 2019-02-08
- Volume
- 15
- Issue
- 10
- Pages
- 1057-1066
- ISSN
- 1479-6694 (ISSN-L)
- 1744-8301
- OpenAlex
- W2914997554
- Cited by
- 171
- References
- 3
- FWCI
- 23.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: KEYNOTE-590: Phase III Study of First-Line Chemotherapy with or Without Pembrolizumab for Advanced Esophageal Cancer. https://app.cochat.ai/papers/10.2217/fon-2018-0609
- The paper
- Kato, K., Shah, M. A., Enzinger, P., Bennouna, J., Shen, L., Adenis, A., Sun, J.-M., Cho, B. C., Özgüroğlu, M., Kojima, T., Kostorov, V., Hierro, C., Zhu, Y., McLean, L. A., Shah, S., & Doi, T. (2019). KEYNOTE-590: Phase III Study of First-Line Chemotherapy with or Without Pembrolizumab for Advanced Esophageal Cancer. Future Oncology. https://doi.org/10.2217/fon-2018-0609
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.